Vivoryon Therapeutics NV (WBO:VVYN) 3-1 Month Momentum %: -3.60% (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:VVYN Vivoryon Therapeutics NV WBO:VVYN
16 GF Score
Price €1.13
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV 3-1 Month Momentum %?

Vivoryon Therapeutics NV WBO:VVYN -0.44% 16 3-1 Month Momentum % is -3.60% as of Aug. 22, 2026. GuruFocus rates WBO:VVYN with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, Vivoryon Therapeutics NV ranks better than 60.89% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-22), Vivoryon Therapeutics NV's 3-1 Month Momentum % is -3.60%.

The industry rank for Vivoryon Therapeutics NV's 3-1 Month Momentum % or its related term are showing as below:

WBO:VVYN's 3-1 Month Momentum % is ranked better than
60.89% of 1386 companies
in the Biotechnology industry
Industry Median: -7.01 vs WBO:VVYN: -3.60

Vivoryon Therapeutics NV  (WBO:VVYN) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Vivoryon Therapeutics NV 3-1 Month Momentum % Related Terms

WBO:VVYN vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Vivoryon Therapeutics NV's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's 3-1 Month Momentum % falls into.


WBO:VVYN
16GF Score
Vivoryon Therapeutics NV WBO:VVYN
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivoryon Therapeutics NV  (WBO:VVYN) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -3.60% mean?
Vivoryon Therapeutics NV (WBO:VVYN) has a 3-1 Month Momentum % of -3.60% as of Aug. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vivoryon Therapeutics NV and its competitors. According to the industry distribution chart, Vivoryon Therapeutics NV ranks #542 out of 1386 companies in the Biotechnology industry, placing it in the top 39.1%.
Is Vivoryon Therapeutics NV's 3-1 Month Momentum % too high?
Vivoryon Therapeutics NV's current 3-1 Month Momentum % is -3.60%. Based on the distribution chart, Vivoryon Therapeutics NV ranks #542 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vivoryon Therapeutics NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivoryon Therapeutics NV ranks #542 out of 1386 companies for 3-1 Month Momentum %. This puts Vivoryon Therapeutics NV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current 3-1 Month Momentum % is -3.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (WBO:VVYN) has a current 3-1 Month Momentum % of -3.60%. The current 3-1 Month Momentum % is -3.60%. Vivoryon Therapeutics NV's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Vivoryon Therapeutics NV (WBO:VVYN), the current 3-1 Month Momentum % is -3.60% as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
16GF Score

Get the complete analysis for WBO:VVYN

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.13
Price